UNSPSC 51392416: Ibopamine hydrochloride

This classification denotes a vasodilating agent with the molecular formula C17H25NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3VXW2HU8GS, chemically known as propanoic acid, 2-methyl-, 4-(2-(methylamino)ethyl)-1,2-phenylene ester but more generally known as ibopamine, which bears US NIH Compound Identifier 68555. European Medicines Agency schedules Ibopamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08094MIG. The term IBOPAMINE HYDROCHLORIDE is an International Non-Proprietary Name.

UNSPSC 51392416 Ibopamine hydrochloride is a Commodity code that nominally identifies a specific pharmaceutical active ingredient, but recent state and local opportunities show little activity directly aligned with this narrow scope. The one substantive recent opportunity—Seminole County, Florida's IFB for naloxone and drug deactivation systems—involves procurement of finished naloxone products for community health and overdose-response support, not ibopamine hydrochloride as a raw pharmaceutical input. A second opportunity from the Texas Health and Human Services Commission (HHS) is an RFI soliciting vendor capabilities for direct-to-manufacturer prescription programs and does not reference ibopamine or any specific active pharmaceutical ingredient. The code appears underutilized or mistagged in current state and local procurement activity, with no clear pattern of issuing bodies or recurring buyers purchasing ibopamine hydrochloride itself.

The geographic spread is limited to Florida and Texas based on recent postings, with no additional states represented in the opportunity block. Seminole County's IFB, posted June 30, 2026, with a response deadline of July 26, 2023 (note: date mismatch in source), seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually via competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford; the procurement includes potential FEMA funding and requires E-Verify compliance and standard insurance coverage. Texas HHS's RFI, posted April 3, 2026, focuses on vendor capabilities for direct pharmaceutical contracting outside traditional pharmacy benefit manager and wholesaler channels rather than procurement of specific drugs. The code shows no substantial recent activity in state and local procurement aligned with ibopamine hydrochloride as a pharmaceutical product or input, making it difficult to assess current market opportunity under this narrow Commodity designation.